ArticleCancer imaging : the official publication of the International Cancer Imaging Society2025
Imaging appearances, CT evolution patterns, and surgical prognosis of stage I lung squamous cell carcinoma.
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Missed Incidental Lung Cancer on Neck CT: Determinants and Impact on Diagnostic Delay and Stage Shift.Korean journal of radiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectivesLung squamous cell carcinoma (LSCC) is a prevalent subtype of lung cancer characterized by a high mortality rate. Early diagnosis and preoperative prognostic prediction are critical for effective patient stratification, guiding clinical management, and ultimately improving patient outcomes. This study aims to investigate the imaging appearances, dynamic changes during follow-up CT, and surgical prognosis of stage I LSCC.
methodsA retrospective analysis was performed on 363 patients with central type (c-LSCC) and 310 patients with peripheral type (p-LSCC). The imaging features of c-LSCC and p-LSCC were first established. Subsequently, the dynamic changes of both types during follow-up CT scans were assessed and compared. Finally, the surgical prognosis for each LSCC type were evaluated.
resultsThe c-LSCC was categorized into two types: type I (endobronchial lesions; 48.76%, 177/363) and type II (hilar nodule or mass; 51.24%, 186/363). Four CT signs were identified: localized bronchial wall thickening (21.49%, 78/363), soft tissue in the bronchial lumen (9.09%, 33/363), bronchial cast shadows (BCS) (76.03%, 276/363), and hilar nodule or mass (51.24%, 186/363). By comparison, the p-LSCC was classified into three categories: type I (solid nodule; 93.22%, 289/310), type II (thin-walled cystic nodule; 6.13%, 19/310), and type III (subsolid nodule; 0.65%, 2/310). Notably, c-LSCC and p-LSCC showed distinct CT evolution patterns. The c-LSCC advanced from endobronchial growth to airway obstruction and BCS development, ultimately forming a hilar mass. While the p-LSCC showed progressive enlargement with malignant features. Stage I c-LSCC had worse disease-free survival (DFS) and overall survival (OS) than p-LSCC (all p < 0.05). Survival analysis revealed that a CT score of BCS ≥ 4 and obstructive pneumonia were independent predictors of poor outcomes for both DFS and OS in patients with c-LSCC (p < 0.05). Conversely, a history of previous malignancy and perifocal fibrosis predicted unfavorable prognosis for both DFS and OS in patients with p-LSCC (p < 0.05).
conclusionEarly-stage LSCC demonstrates distinct imaging characteristics, CT evolution patterns, and surgical prognosis between central and peripheral subtypes, informing early diagnosis and personalized management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.